[go: up one dir, main page]
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 1
1989 3
1990 2
1991 4
1992 2
1993 1
1994 3
1996 1
1997 3
1998 3
1999 3
2000 8
2001 9
2002 16
2003 17
2004 21
2005 17
2006 16
2007 13
2008 18
2009 30
2010 20
2011 21
2012 22
2013 22
2014 29
2015 19
2016 24
2017 31
2018 33
2019 34
2020 30
2021 38
2022 34
2023 26
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

490 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Thompson AJ, et al. Among authors: uitdehaag bmj. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Lancet Neurol. 2018. PMID: 29275977 Review.
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Walton C, et al. Among authors: uitdehaag b. Mult Scler. 2020 Dec;26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11. Mult Scler. 2020. PMID: 33174475 Free PMC article.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
Rodriguez-Mogeda C, van Lierop ZYGJ, van der Pol SMA, Coenen L, Hogenboom L, Kamermans A, Rodriguez E, van Horssen J, van Kempen ZLE, Uitdehaag BMJ, Teunissen CE, Witte ME, Killestein J, de Vries HE. Rodriguez-Mogeda C, et al. Among authors: uitdehaag bmj. J Neuroinflammation. 2023 Sep 26;20(1):215. doi: 10.1186/s12974-023-02900-z. J Neuroinflammation. 2023. PMID: 37752582 Free PMC article.
Biomarker time out.
Petzold A, Bowser R, Calabresi P, Zetterberg H, Uitdehaag BM. Petzold A, et al. Among authors: uitdehaag bm. Mult Scler. 2014 Oct;20(12):1560-3. doi: 10.1177/1352458514524999. Epub 2014 Feb 20. Mult Scler. 2014. PMID: 24557857 Review.
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Lublin F, et al. Among authors: uitdehaag bmj. Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Lancet. 2016. PMID: 26827074 Free article. Clinical Trial.
Cell-based therapeutic strategies for multiple sclerosis.
Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis. Scolding NJ, et al. Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Brain. 2017. PMID: 29053779 Free PMC article. Review.
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
van Lierop ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, Strijbis EM, de Jong BA, van Oosten BW, Moraal B, Teunissen CE, Uitdehaag BM, Killestein J, Kempen ZLV. van Lierop ZY, et al. Among authors: uitdehaag bm. Mult Scler. 2022 Jun;28(7):1121-1125. doi: 10.1177/13524585211028833. Epub 2021 Jul 9. Mult Scler. 2022. PMID: 34240631 Free PMC article.
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.
Toorop AA, Hogenboom L, Bloem K, Kocyigit M, Commandeur NWM, Wijnants A, Lissenberg-Witte BI, Strijbis EMM, Uitdehaag BMJ, Rispens T, Killestein J, van Kempen ZLE. Toorop AA, et al. Among authors: uitdehaag bmj. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):487-493. doi: 10.1136/jnnp-2022-330793. Epub 2023 Jan 24. J Neurol Neurosurg Psychiatry. 2023. PMID: 36693720
490 results